EUVIMEDEUVIMED entdecken
Crossref

Circulating Cell‐Free Mitochondrial DNA as a Prognostic Biomarker in Patients With HBV‐Related Acute‐on‐Chronic Liver Failure

Qiankun Hu, Jiajia Han, Chong Chen, Shuai Tao, Chenlu Huang, Jiacheng Lin, Xun Qi, Zhiping Qian, Mengxin Lu, Xinyan Li, Yi Zhang, Xuhua Jiang und 8 weitere

Journal of Medical Virology · 2025

DOI: 10.1002/jmv.70551 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Qiankun Hu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Acute-On-Chronic Liver Failure, DNA, Mitochondrial, Biomarkers, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: This work was supported by the grants from Shanghai Hospital Development Center Foundation (SHDC12021114), the National Natural Science Foundation of China (81….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute‐on‐chronic liver failure (ACLF), particularly hepatitis B virus‐related ACLF (HBV‐ACLF), is a severe condition with high short‐term mortality. This study aimed to evaluate the prognostic value of circulating cell‐free mitochondrial DNA (cf‐mtDNA) in predicting short‐term mortality in HBV‐ACLF patients. A total of 320 HBV‐ACLF patients were included in the study population, with 192 patients in the derivation cohort and 128 in the validation cohort. Plasma cf‐mtDNA levels were quantified using qPCR. Plasma cf‐mtDNA levels were significantly elevated in HBV‐ACLF patients (3.95 log 10 copies/μL) compared to healthy controls (2.99 log 10 copies/μL) and patients with chronic liver disease (3.03 log 10 copies/μL) ( p < 0.001). Plasma cf‐mtDNA levels progressively increased with disease severity and were associated with multi‐organ failure. Sequential measurements of cf‐mtDNA showed a significant decrease in survivors (4.00 vs. 3.78 log 10 copies/μL, p = 0.019), while non‐survivors maintained persistently elevated levels with minimal change (4.19 vs. 4.15 log 10 copies/μL, p = 0.359). The cut‐off value of 3.9 log 10 copies/μL for cf‐mtDNA effectively stratified patients into high‐ and low‐risk groups, with significantly lower survival rates in the high‐risk group (28‐day: 46.2% vs. 86.0%, p < 0.001; 90‐day: 37.7% vs. 72.1%, p < 0.001). Using cf‐mtDNA in combination with key clinical parameters, we developed a novel prognostic score that exhibited superior predictive accuracy for 28‐ and 90‐day mortality (AUROCs: 0.907 and 0.906, respectively), outperforming established prognostic scores (all p < 0.05). These findings were validated in an independent cohort. Cf‐mtDNA is a superior biomarker for predicting short‐term mortality in HBV‐ACLF. Its association with multi‐organ failure and disease severity highlights the potential utility in early risk assessment and treatment optimization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute-On-Chronic Liver FailureDNA, MitochondrialBiomarkersCell-Free Nucleic AcidsHepatitis B, ChronicHepatitis BHumansMaleFemalePrognosisMiddle AgedAdultAgedHepatitis B virus

Stichwörter der Autor:innen

acute‐on‐chronic liver failurecell‐free mitochondrial DNAhepatitis B virusprognostic biomarker

Substanzen

DNA, MitochondrialBiomarkersCell-Free Nucleic Acids

Autor:innen und Institutionen

  • Department of Liver Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
  • Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
  • Department of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
  • Central Laboratory, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Department of Liver Intensive Care Unit, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.

ORCID-Profile: Jianming Zheng, Jiming Zhang, Xueyun Zhang, Yuxian Huang

Förderung

  • This work was supported by the grants from Shanghai Hospital Development Center Foundation (SHDC12021114), the National Natural Science Foundation of China (81…

Zitieren

APA

Hu, Q., Han, J., Chen, C., Tao, S., Huang, C., Lin, J., Qi, X., Qian, Z., Lu, M., Li, X., Zhang, Y., Jiang, X., Zheng, J., Zhao, H., Yang, F., Zhang, J., Chen, L., Kong, X., Zhang, X., & Huang, Y. (2025). Circulating Cell‐Free Mitochondrial DNA as a Prognostic Biomarker in Patients With HBV‐Related Acute‐on‐Chronic Liver Failure. Journal of Medical Virology. https://doi.org/10.1002/jmv.70551

Vancouver

Hu Q, Han J, Chen C, Tao S, Huang C, Lin J, et al. Circulating Cell‐Free Mitochondrial DNA as a Prognostic Biomarker in Patients With HBV‐Related Acute‐on‐Chronic Liver Failure. Journal of Medical Virology. 2025. doi:10.1002/jmv.70551

BibTeX
@article{Hu2025,
  author = {Hu, Qiankun and Han, Jiajia and Chen, Chong and Tao, Shuai and Huang, Chenlu and Lin, Jiacheng and Qi, Xun and Qian, Zhiping and Lu, Mengxin and Li, Xinyan and Zhang, Yi and Jiang, Xuhua and Zheng, Jianming and Zhao, Huazhen and Yang, Feifei and Zhang, Jiming and Chen, Liang and Kong, Xiaoni and Zhang, Xueyun and Huang, Yuxian},
  title = {Circulating Cell‐Free Mitochondrial DNA as a Prognostic Biomarker in Patients With HBV‐Related Acute‐on‐Chronic Liver Failure},
  journal = {Journal of Medical Virology},
  year = {2025},
  doi = {10.1002/jmv.70551}
}
Kostenlos starten →